The emerging role of vascular endothelial growth factor (VEGF) in vascular homeostasis: lessons from recent trials with anti-VEGF drugs

S Thanigaimani, Ganessan Kichenadasse, Arduino Aleksander Mangoni

Research output: Contribution to journalArticle

21 Citations (Scopus)
3 Downloads (Pure)

Abstract

Vascular endothelial growth factor (VEGF) is an endogenous polypeptide that modulates angiogenesis in normal physiological conditions as well as in cancer. During angiogenesis, VEGF interacts with several other angiogenic factors, playing an important role in cell proliferation, differentiation, migration, cell survival, nitric oxide (NO) production, release of other growth factors and sympathetic innervation. Based on these mechanisms of action, several anti-VEGF drugs have been developed for cancer treatment. This review discusses the physiology and interactions of VEGF, its mechanisms of action and role in modulating vascular homeostasis. It also discusses the adverse cardiovascular effects of recently developed anti-VEGF drugs for the treatment of various types of cancer. A critical appraisal of the human studies on these drugs is provided. Furthermore, putative mechanisms for the onset of hypertension, the most common adverse cardiovascular effect, are discussed.
Original languageEnglish
Pages (from-to)358-380
Number of pages23
JournalCurrent Vascular Pharmacology
Volume9
Issue number3
DOIs
Publication statusPublished - May 2011

Fingerprint

Vascular Endothelial Growth Factor A
Blood Vessels
Homeostasis
Pharmaceutical Preparations
Neoplasms
Angiogenesis Inducing Agents
Cell Differentiation
Cell Survival
Intercellular Signaling Peptides and Proteins
Nitric Oxide
Cell Proliferation
Hypertension
Peptides

Keywords

  • vascular endothelial growth factor
  • angiogenesis
  • endothelium
  • homeostasis
  • cardiotoxicity
  • hypertension
  • nitric oxide
  • clinical trials
  • vascular endothelial growth factor receptor
  • renin angiostensin system
  • cytokines
  • interleukin

Cite this

The emerging role of vascular endothelial growth factor (VEGF) in vascular homeostasis : lessons from recent trials with anti-VEGF drugs. / Thanigaimani, S; Kichenadasse, Ganessan; Mangoni, Arduino Aleksander.

In: Current Vascular Pharmacology, Vol. 9, No. 3, 05.2011, p. 358-380.

Research output: Contribution to journalArticle

Thanigaimani, S ; Kichenadasse, Ganessan ; Mangoni, Arduino Aleksander. / The emerging role of vascular endothelial growth factor (VEGF) in vascular homeostasis : lessons from recent trials with anti-VEGF drugs. In: Current Vascular Pharmacology. 2011 ; Vol. 9, No. 3. pp. 358-380.
@article{eff4a22892ff48f9a478ee2d70745013,
title = "The emerging role of vascular endothelial growth factor (VEGF) in vascular homeostasis: lessons from recent trials with anti-VEGF drugs",
abstract = "Vascular endothelial growth factor (VEGF) is an endogenous polypeptide that modulates angiogenesis in normal physiological conditions as well as in cancer. During angiogenesis, VEGF interacts with several other angiogenic factors, playing an important role in cell proliferation, differentiation, migration, cell survival, nitric oxide (NO) production, release of other growth factors and sympathetic innervation. Based on these mechanisms of action, several anti-VEGF drugs have been developed for cancer treatment. This review discusses the physiology and interactions of VEGF, its mechanisms of action and role in modulating vascular homeostasis. It also discusses the adverse cardiovascular effects of recently developed anti-VEGF drugs for the treatment of various types of cancer. A critical appraisal of the human studies on these drugs is provided. Furthermore, putative mechanisms for the onset of hypertension, the most common adverse cardiovascular effect, are discussed.",
keywords = "vascular endothelial growth factor, angiogenesis, endothelium, homeostasis, cardiotoxicity, hypertension, nitric oxide, clinical trials, vascular endothelial growth factor receptor, renin angiostensin system, cytokines, interleukin",
author = "S Thanigaimani and Ganessan Kichenadasse and Mangoni, {Arduino Aleksander}",
year = "2011",
month = "5",
doi = "10.2174/157016111795495503",
language = "English",
volume = "9",
pages = "358--380",
journal = "Current Vascular Pharmacology",
issn = "1570-1611",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - The emerging role of vascular endothelial growth factor (VEGF) in vascular homeostasis

T2 - lessons from recent trials with anti-VEGF drugs

AU - Thanigaimani, S

AU - Kichenadasse, Ganessan

AU - Mangoni, Arduino Aleksander

PY - 2011/5

Y1 - 2011/5

N2 - Vascular endothelial growth factor (VEGF) is an endogenous polypeptide that modulates angiogenesis in normal physiological conditions as well as in cancer. During angiogenesis, VEGF interacts with several other angiogenic factors, playing an important role in cell proliferation, differentiation, migration, cell survival, nitric oxide (NO) production, release of other growth factors and sympathetic innervation. Based on these mechanisms of action, several anti-VEGF drugs have been developed for cancer treatment. This review discusses the physiology and interactions of VEGF, its mechanisms of action and role in modulating vascular homeostasis. It also discusses the adverse cardiovascular effects of recently developed anti-VEGF drugs for the treatment of various types of cancer. A critical appraisal of the human studies on these drugs is provided. Furthermore, putative mechanisms for the onset of hypertension, the most common adverse cardiovascular effect, are discussed.

AB - Vascular endothelial growth factor (VEGF) is an endogenous polypeptide that modulates angiogenesis in normal physiological conditions as well as in cancer. During angiogenesis, VEGF interacts with several other angiogenic factors, playing an important role in cell proliferation, differentiation, migration, cell survival, nitric oxide (NO) production, release of other growth factors and sympathetic innervation. Based on these mechanisms of action, several anti-VEGF drugs have been developed for cancer treatment. This review discusses the physiology and interactions of VEGF, its mechanisms of action and role in modulating vascular homeostasis. It also discusses the adverse cardiovascular effects of recently developed anti-VEGF drugs for the treatment of various types of cancer. A critical appraisal of the human studies on these drugs is provided. Furthermore, putative mechanisms for the onset of hypertension, the most common adverse cardiovascular effect, are discussed.

KW - vascular endothelial growth factor

KW - angiogenesis

KW - endothelium

KW - homeostasis

KW - cardiotoxicity

KW - hypertension

KW - nitric oxide

KW - clinical trials

KW - vascular endothelial growth factor receptor

KW - renin angiostensin system

KW - cytokines

KW - interleukin

U2 - 10.2174/157016111795495503

DO - 10.2174/157016111795495503

M3 - Article

VL - 9

SP - 358

EP - 380

JO - Current Vascular Pharmacology

JF - Current Vascular Pharmacology

SN - 1570-1611

IS - 3

ER -